Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 93.11B 83.39B 76.71B 69.5B 130B 8,841B 132B 915B 367B 4,651B 349B 342B 14,666B P/E 2026 *
14.4x
P/E 2027 * 16.2x
Enterprise Value 85.69B 76.74B 70.59B 63.96B 120B 8,136B 122B 842B 338B 4,280B 322B 315B 13,497B EV / Sales 2026 *
4.87x
EV / Sales 2027 * 4.17x
Free-Float
71.06%
Yield 2026 *
0.41%
Yield 2027 * 0.46%
1 day+13.33%
1 week+15.26%
1 month+22.37%
3 months+21.67%
6 months+31.23%
Current year+20.21%
1 week 796.61
Extreme 796.61
935.35
1 month 722.02
Extreme 722.02
935.35
Current year 591.52
Extreme 591.52
935.35
1 year 591.52
Extreme 591.52
935.35
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 2000-12-31
Chief Executive Officer 73 1988-01-07
Director of Finance/CFO 55 2024-02-04
Director TitleAgeSince
Chairman 73 2023-06-08
Director/Board Member 85 1991-05-31
Director/Board Member 76 1988-01-07
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/26 Sell

Chief Technology Officer

-4,147 0.0041%
9/3/26 Sell

Executive/Senior Manager

-1,131 0.0011%
9/2/26 Exercice

Director

1,200 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+13.33%+15.26%+42.36%+18.98% 93.11B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +3.21%+6.84%+46.16%+78.00% 435.5B
Weighted average by Cap. +2.25%+6.78%+50.33%+98.69%

Financials

2026 *2027 *
Net sales 17.6B 15.77B 14.5B 13.14B 24.56B 1,672B 25.02B 173B 69.43B 879B 66.07B 64.66B 2,773B 19.59B 17.54B 16.14B 14.62B 27.33B 1,860B 27.84B 192B 77.25B 978B 73.51B 71.95B 3,085B
Net income 6.65B 5.95B 5.48B 4.96B 9.27B 631B 9.45B 65.3B 26.21B 332B 24.94B 24.41B 1,047B 6.1B 5.46B 5.03B 4.55B 8.51B 579B 8.67B 59.94B 24.06B 305B 22.9B 22.41B 961B
Net Debt -7.42B -6.65B -6.12B -5.54B -10.36B -705B -10.55B -72.93B -29.28B -371B -27.86B -27.27B -1,169B -11.48B -10.28B -9.46B -8.57B -16.02B -1,090B -16.32B -113B -45.27B -573B -43.08B -42.16B -1,808B
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
26-10-30 $927.89 +13.33% 2,870,752
26-10-29 $818.77 +0.68% 789,303
26-10-28 $813.27 -0.35% 536,498
26-10-27 $816.10 +1.04% 726,151
26-10-26 $807.67 +0.33% 423,958
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
927.89USD
Average target price
929.00USD
Spread / Average Target
+0.12%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Regeneron Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. REGN Stock